Literature DB >> 2863759

Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines.

J R Riordan, K Deuchars, N Kartner, N Alon, J Trent, V Ling.   

Abstract

The multidrug-resistance phenotype expressed in mammalian cell lines is complex. Cells selected with a single agent can acquire cross-resistance to a remarkably wide range of compounds which have no obvious structural or functional similarities. The basis for cross-resistance seems to be a decreased net cellular accumulation of the drug involved, and has been attributed to alterations in the plasma membrane. An over-expressed plasma membrane glycoprotein of relative molecular mass (Mr) 170,000 (P-glycoprotein) is consistently found in different multidrug-resistant human and animal cell lines, and in transplantable tumours. Consequently, it has been postulated that P-glycoprotein directly or indirectly mediates multidrug resistance. Here we report the cloning of a complementary DNA encoding P-glycoprotein. Southern blot analysis of hamster, mouse and human DNA using this cDNA as a probe showed that P-glycoprotein is conserved and is probably encoded by a gene family, and that members of this putative family are amplified in multidrug-resistant cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2863759     DOI: 10.1038/316817a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  182 in total

1.  Regulation of P-glycoprotein gene expression in hepatocyte cultures and liver cell lines by a trans-acting transcriptional repressor.

Authors:  T W Gant; J A Silverman; S S Thorgeirsson
Journal:  Nucleic Acids Res       Date:  1992-06-11       Impact factor: 16.971

Review 2.  Genetic aspects of multidrug resistance.

Authors:  M Pauly; F Ries; M Dicato
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

Review 3.  Drug resistance in oncology: from concepts to applications.

Authors:  J L Cazin; P Gosselin; P Cappelaere; J Robert; A Demaille
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 4.  [Personalized drug therapy based on genetics. Possibilities and examples from clinical practice].

Authors:  J C Stingl; K S Just; K Kaumanns; M Schurig-Urbaniak; C Scholl; D von Mallek; J Brockmöller
Journal:  Internist (Berl)       Date:  2016-03       Impact factor: 0.743

Review 5.  ABC transporters and their role in nucleoside and nucleotide drug resistance.

Authors:  Yu Fukuda; John D Schuetz
Journal:  Biochem Pharmacol       Date:  2012-01-20       Impact factor: 5.858

Review 6.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Malignant phenotype correlating with drug resistance in two human neuroblastoma cell lines.

Authors:  Y Wollman; I Shahar; M Goldstein; J Leibovici
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 8.  Topoisomerase inhibitors. A review of their therapeutic potential in cancer.

Authors:  B K Sinha
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

9.  Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in Drosophila.

Authors:  Fahima Mayer; Nasima Mayer; Leslie Chinn; Robert L Pinsonneault; Deanna Kroetz; Roland J Bainton
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

10.  Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdr1 gene.

Authors:  D W Shen; A Fojo; I B Roninson; J E Chin; R Soffir; I Pastan; M M Gottesman
Journal:  Mol Cell Biol       Date:  1986-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.